UNSPSC 51273602: Vinyl ether

This classification denotes an anesthetic with the molecular formula C4H6O, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 2H2T044E11, chemically known as 1,1-oxybisethene but generally known as vinyl ether, which bears US NIH Compound Identifier 8024. European Medicines Agency schedules Vinyl ether in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB15697MIG. World Health Organization schedules vinyl ether in its Anatomical Therapeutic Chemical (ATC) Classification.

As of Q4 2014, VINYL ETHER remains the US FDA Preferred Term for this commodity. SMILES: C=COC=C.

UNSPSC 51273602 Vinyl ether (Commodity) captures pharmaceutical and health-supply procurement by state and local governments, though recent solicitations under this code show minimal activity directly aligned with the vinyl ether category itself. The three recent opportunities on file—Seminole County's naloxone and drug deactivation systems bid, Texas HHS's direct-to-manufacturer prescription RFI, and Minnesota's multistate cooperative pharmaceuticals RFP—indicate state and local procurement of finished pharmaceutical products, OTC medications, and medical countermeasures rather than chemical precursors or specialty ether compounds. State health departments, county health authorities, and multistate cooperative purchasing alliances dominate the issuing-body mix; Seminole County and Texas HHS appear as active buyers, while the Minnesota Multistate Cooperative Purchasing Alliance (MMCAP) represents a cooperative vehicle serving multiple state and local jurisdictions across participating members including Oregon.

Recent activity concentrates in the South and Upper Midwest. Seminole County, Florida posted an IFB (IFB60459723LAS) on June 30, 2026, with a July 26, 2023 response deadline, seeking annual procurement of 1,900 units of naloxone and 800 safe drug deactivation systems with quarterly deliveries; the contract carries a two-year initial term with one-year renewal option and includes FEMA funding compliance. Texas HHS issued an RFI (HHS0017013) on April 3, 2026, to gather vendor capabilities for a direct-to-manufacturer prescription program without formal evaluation criteria or award amounts. Minnesota's MMCAP released an RFP (S1070000015802) on January 20, 2026, due March 26, 2026, for generic multi-source pharmaceuticals and OTC products supplied through three authorized wholesalers, with contract terms beginning July 1, 2026, weighted heavily on price competitiveness (75 percent) and requiring cGMP and DSCSA compliance. The code shows limited true vinyl ether procurement in recent state and local filings.